克里唑蒂尼
间变性淋巴瘤激酶
医学
间变性大细胞淋巴瘤
碱性抑制剂
淋巴瘤
癌症研究
内科学
肿瘤科
肺癌
恶性胸腔积液
作者
Özkan Alan,Okan Kuzhan,Sinan Koca,Tuğba Akın Telli,Tuğba Başoğlu,Özlem Ercelep,Deniz Filinte,Yildiz Sengul,Hüseyin Arıkan,Serap Kaya,Nalân Akgül Babacan,Faysal Dane,Perran Fulden Yumuk
标识
DOI:10.1177/1078155219879757
摘要
Inflammatory myofibroblastic tumor is a rare disease which is typically seen in children and young adults. Approximately half of the inflammatory myofibroblastic tumors contain translocations that result in over-expression of anaplastic lymphoma kinase gene. Herein, we present two anaplastic lymphoma kinase-positive cases with long-term remission with crizotinib. We do not know how long these therapies need to be continued.We present two cases of inflammatory myofibroblastic tumor treated with anaplastic lymphoma kinase inhibitor therapies: an 8-year-old Turkish boy and a 21-year-old Caucasian man.Two cases, both with good tumor control under crizotinib, but one who progressed on drug holiday, responded again to the same drug, and had a very short period of response after restarting crizotinib.A molecular-targeted drug (anaplastic lymphoma kinase inhibitor) was found to be extremely effective as selective therapy for inflammatory myofibroblastic tumor with anaplastic lymphoma kinase translocation. Here, we want to emphasize the continuation of this treatment after achieving a good response until progression or a major side effect.
科研通智能强力驱动
Strongly Powered by AbleSci AI